arrow_back Back to App

Glioblastoma Awareness Day: Support for Patients and Research

The U.S. House of Representatives supports designating July 16, 2025, as Glioblastoma Awareness Day. This aims to increase public understanding of this aggressive disease, honor those affected, and encourage further research into new treatments. Citizens will gain greater awareness of this rare but deadly disease, potentially fostering support for research initiatives and improved care.
Key points
Designation of July 16, 2025, as Glioblastoma Awareness Day to increase public awareness.
Support for developing better glioblastoma treatments to improve patient prognosis and quality of life.
Encouragement of continued investment in glioblastoma research, including through the Glioblastoma Therapeutics Network.
Recognition of the importance of molecular biomarker testing for glioblastoma diagnosis and treatment.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HRES_394
Sponsor: Rep. Williams, Roger [R-TX-25]
Process start date: 2025-05-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing support for the designation of July 16, 2025, as "Glioblastoma Awareness Day".

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HRES_394.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-05-06.

What are the main provisions?

Key points include:

  • Designation of July 16, 2025, as Glioblastoma Awareness Day to increase public awareness.
  • Support for developing better glioblastoma treatments to improve patient prognosis and quality of life.
  • Encouragement of continued investment in glioblastoma research, including through the Glioblastoma Therapeutics Network.
  • Recognition of the importance of molecular biomarker testing for glioblastoma diagnosis and treatment.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Williams, Roger [R-TX-25].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-21.

CATEGORIES

Health